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Abstract
Background: The tumor suppressor Programmed Cell Death 4 (PDCD4) has been found to be under-expressed in
several cancers and associated with disease progression and metastasis. There are no current studies characterizing
PDCD4 expression and its clinical relevance in Oral Squamous Cell Carcinoma (OSCC). Since nodal metastasis is a
major prognostic factor in OSCC, we focused on determining whether PDCD4 under-expression was associated
with patient nodal status and had functional relevance in OSCC invasion. We also examined PDCD4 regulation by
microRNA 21 (miR-21) in OSCC.
Results: PDCD4 mRNA expression levels were assessed in 50 OSCCs and 25 normal oral tissues. PDCD4 was under-
expressed in 43/50 (86%) OSCCs, with significantly reduced mRNA levels in patients with nodal metastasis (p=
0.0027), and marginally associated with T3-T4 tumor stage (p = 0.054). PDCD4 protein expression was assessed, by
immunohistochemistry (IHC), in 28/50 OSCCs and adjacent normal tissues; PDCD4 protein was absent/under-
expressed in 25/28 (89%) OSCCs, and marginally associated with nodal metastasis (p = 0.059). A matrigel invasion
assay showed that PDCD4 expression suppressed invasion, and siRNA-mediated PDCD4 loss was associated with
increased invasive potential of oral carcinoma cells. Furthermore, we showed that miR-21 levels were increased in
PDCD4-negative tumors, and that PDCD4 expression may be down-regulated in OSCC by direct binding of miR-21
to the 3′UTR PDCD4 mRNA.
Conclusions: Our data show an association between the loss of PDCD4 expression, tumorigenesis and invasion in
OSCC, and also identify a mechanism of PDCD4 down-regulation by microRNA-21 in oral carcinoma. PDCD4
association with nodal metastasis and invasion suggests that PDCD4 may be a clinically relevant biomarker with
prognostic value in OSCC.
Introduction
Oral squamous cell carcinomas (OSCCs) are malignant
oral cavity tumors that account for 24% of all head and
neck cancers [1]. The presence of lymph node metasta-
sis (regional disease) affects more than 50% of OSCC
patients and it is one of the most important prognostic
indicators associated with poor patient survival [2,3].
The probability of distant metastases increases when
there is cervical node involvement and survival rates
decrease by approximately 50% [4]. Detection of nodal
metastasis is important at diagnosis; clinical staging of
neck nodes is determined by physical examination of
enlarged lymph nodes and imaging. However, even
when no nodal involvement is detected, there is still a
high incidence (> 20%) of occult neck metastasis [3].
These factors contribute to the high morbidity and mor-
tality rates of patients with OSCC. Based on the hypoth-
esis that metastatic potential may be determined by the
genetic properties of the primary tumor [5], studies
focused on the ability of biomarkers to predict meta-
static potential are urgently needed. Such studies may
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Recently, Programmed Cell Death 4 (PDCD4) has been
strongly associated with the progression and metastasis of
multiple human cancer types. PDCD4 was first identified
as a transformation suppressor gene in a mouse keratino-
cyte (JB6 cells) model of tumor promotion, in which high
PDCD4 levels rendered cells resistant to transformation
by the tumor-promoter 12-O-tetradecanoyl-phorbol-13-
acetate (TPA) [6]. PDCD4 is known to play a role in apop-
tosis but its specific mechanism has yet to be determined.
Recent studies indicate that PDCD4 may have important
roles in transcription, translation, and signal transduction
pathways (reviewed in [7]). PDCD4 has been suggested to
function as a tumor suppressor, with reduced expression
levels in cell lines derived from different tumor types
[8-10]. PDCD4 levels were also decreased in primary
patient tumor samples from lung cancer [8], hepatocellular
carcinoma [10], breast carcinoma [11], colon cancer
[12,13], glioma [14], pancreatic cancer [15] and esophageal
carcinoma [16]. In epithelial tumors, such as breast cancer,
PDCD4 protein expression levels were slightly reduced in
ductal carcinoma in situ, but markedly decreased in inva-
sive ductal carcinoma, suggesting that its loss may be
required for invasion [17]. In colon carcinoma, PDCD4
over-expression was shown to decrease the invasive poten-
tial of cancer cells [18], and its under-expression enhanced
cancer cell invasion [13].
microRNA (miR) target prediction databases suggest
that PDCD4 is regulated by microRNA-21 (miR-21)
[19,20]. Recently, PDCD4 has been shown to be regu-
lated by miR-21 in other cancers, such as colon carci-
noma [21]. It is known that microRNAs inhibit the
expression of their target genes by degradation of target
mRNA and/or translationalr e p r e s s i o no fm R N Aw i t h -
out degradation [22]. Interestingly, we recently showed
that increasing miR-21 levels were significantly asso-
ciated with progression of oral carcinoma lesions [23].
B i n d i n go fm i R - 2 1t oP D C D 4m a yt h u sb eap o t e n t i a l
mechanism of PDCD4 regulation in OSCC.
Recent experimental evidence suggests that PDCD4
function may be different according to cell type [7],
thus highlighting the relevance of studying PDCD4
expression, its regulatory mechanism and its role in dif-
ferent cell and tissue types. Herein, we showed that
PDCD4 levels were significantly decreased in OSCCs
from node positive patients. We also demonstrated that
PDCD4 is involved in invasion of oral carcinoma cells.
O u rd a t as u p p o r tar o l ef o rP D C D 4i nO S C Ci n v a s i o n
and metastasis. Further, we demonstrated that PDCD4
is regulated by miR-21 in OSCC. PDCD4 may have
clinical utility for prediction, at the time of diagnosis, of
which OSCCs may have a higher risk of neck nodal
metastasis.
Results
QPCR results in relation to clinical data
PDCD4 mRNA levels were decreased in 43/50 (86%)
OSCCs, unchanged in six tumors and increased in one
tumor (median, 0.28, range 0.05-2.82) compared to adja-
cent normal oral tissues (PDCD4 expression level in
normal oral mucosa = 1). Lower PDCD4 mRNA levels
were detected in OSCCs from patients with more
advanced tumor stage (median, 0.25 vs.0 . 3 5 ,p = 0.054),
and were lower (median, 0.16 vs. 0.34; p = 0.0027)i n
tumors from patients with nodal metastasis (Figure 1).
PDCD4 mRNA levels were not significantly different
between other clinical variables.
PDCD4 mRNA levels, survival and disease-free survival
(DFS)
Univariate analysis of survival and DFS showed that
patients with lower PDCD4 mRNA levels showed worse
survival (HR = 0.014, 95% CI: 0.001-0.39, p = 0.0118)
and poorer DFS (HR = 0.134, 95% CI: 0.019-0.961, p=
0.0456) (Figure 2). Multivariate analysis including var-
ious clinical factors (e.g., perineural invasion, stage)
yielded similar results; lower PDCD4 mRNA levels were
associated with poorer survival (HR = 0.022, 95% CI:
0.001-0.713, p = 0.0315) and poorer DFS (HR = 0.12,
95% CI: 0.016-0.927, p = 0.0421). In the multivariate
analysis, PDCD4 protein levels (as determined by IHC)
were also associated with poorer DFS (HR = 0.564, 95%
CI: 0.339-0.937, p = 0.0272). Although decreased
PDCD4 mRNA and/or protein levels were associated
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Figure 1 Significantly lower PDCD4 mRNA levels were detected
in OSCCs from node-positive patients (N+) as compared with
node-negative patients (N0) (p = 0.0027). Median PDCD4
expression in node-positive tumors was 0.16 versus 0.34 in node-
negative tumors. The x-axis shows the nodal status (N0, N+), and
the y-axis represents PDCD4 mRNA levels normalized against
GAPDH and normal oral mucosa. In normal oral mucosa tissues
(used as baseline control sample), PDCD4 expression levels were
defined as 1, according to the Delta Delta Ct method of data
analysis. Error bars represent standard error.
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Page 2 of 13with survival and/or DFS, these data are based on a
small cohort of 50 patients.
IHC results and correlation with clinical data
Immunohistochemical analysis showed that PDCD4 was
strongly expressed in the nuclei of normal oral squa-
mous epithelia (Figure 3, panels A and D). Nuclear
PDCD4 staining was observed in dysplasia adjacent to
the tumor, although with decreased intensity (Figure 3,
panels B and E). PDCD4 expression was absent in the
basal layer of normal and dysplasia samples. Overall,
PDCD4 protein was absent/under-expressed in 25/28
(89%) of OSCCs (Figure 3, panels C and F), and margin-
ally associated with nodal metastasis (p = 0.059).
PDCD4 mRNA and protein levels were correlated (Wil-
coxon signed rank, p = 0.002).
PDCD4 expression in UT-SCC cell lines
PDCD4 mRNA and protein expression levels were
assessed in the UT-SCC cell lines. PDCD4 mRNA and
protein levels were decreased in all cell lines, compared
to the normal oral keratinocyte cell line (HOK)
(Figure 4). UT-SCC-74A exhibited the lowest levels of
PDCD4 mRNA and protein (Relative Ratio to HOK
(RR) = 0.23), while UT-SCC-24A and 87 expressed
similar levels of PDCD4 mRNA and protein levels
(RR = 0.49, and 0.43, respectively).
PDCD4 and tumor cell invasion
The optimal amount of transfected PDCD4 or PCMV6
control plasmids were tested by measuring the toxicity
of various amounts of plasmid in UT-SCC-24A. We
found that both 200 ng and 500 ng of PDCD4 plasmid
led to an increase in PDCD4 mRNA and protein com-
pared to the control. A plasmid concentration of
> 500 ng was toxic to the cells (< 60% cell viability after
72 hrs) [see Additional file 1]. We then tested whether
UT-SCC-24A would invade through a matrigel following
transfection of 200 ng or 500 ng of PDCD4 compared to
PCMV6; 200 ng of PDCD4 plasmid effectively decreased
invasion compared to control (22 ± 6% vs. 80 ± 11%)
and it was used for all subsequent experiments [see
Additional file 2]. 500 ng PDCD4 and PCMV6 control
plasmid also decreased invasion (1 ± 0% vs. 24 ± 2%).
Next, we determined the effect of over-expressing and
silencing PDCD4 in UT-SCC-24A, 74A, and 87. Effec-
tive over-expression and knock-down of PDCD4 was
confirmed by Western blot (Figure 5). Post-transfection,
PDCD4 over-expression resulted in a significant
decrease in the percentage of invading cells in all three
cell lines, compared to mock-transfected control
(Figure 6). Conversely, knock-down of PDCD4 signifi-
cantly increased the number of invading cells in all cell
lines, compared to mock-transfected control (Figure 6).
These data suggested a role for PDCD4 in regulating
OSCC invasion.
miR-21 and PDCD4 in OSCC
Since miR-21 is over-expressed and it has been shown
to regulate PDCD4 in other cancers [21,24], we sought
to determine whether miR-21 regulates PDCD4 in
OSCC. First, we found that miR-21 was over-expressed
(median, 12.79, range 2.78 - 63.67) in 28/28 primary
patient OSCCs, as compared to normal tongue RNA
(expression = 1). Next, we sought to investigate whether
miR-21 regulated endogenous PDCD4 in UT-SCC cell
lines, by examining the effect of transient transfection of
miR-21 on PDCD4 protein levels. We transfected a
range (25, 50, 75 or 100 pmol) of scramble-miR into
UT-SCC-74A to determine the optimal plasmid concen-
tration at 72 hrs. of transfection, without causing signifi-
cant toxicity to the cells. We found that only 25 or 50
pmol of scramble-miR did not significantly decrease cell
viability (91.3 ± 5.7% and 89.3 ± 2.4%, respectively)
Figure 2 A) Survival and B) Disease-Free Survival (DFS) of
OSCC patients, according to PDCD4 mRNA levels. DFS analysis
showed 28 events (23 recurrences and 5 deaths without
recurrence). Median PDCD4 expression at 0.28 was used as the
cutoff point, which is regarded as unbiased.
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Page 3 of 13compared to mock-transfected. We tested the effect of
transfection using 25 and 50 pmol of scramble-miR,
pre-miR-21 and anti-miR-21 and both concentrations
were confirmed as non-toxic to cells. By TaqMan real-
time PCR, we confirmed that pre-miR-21 and anti-miR-
21 led to over-expression and knock-down of miR-21,
respectively. We found that pre-miR-21 successfully
inhibited PDCD4 protein expression in all cell lines.
Anti-miR-21 successfully up-regulated PDCD4 protein
expression in UT-SCC-74A, and it only had a slight
effect on PDCD4 expression in UT-SCC-24A and 87
(Figure 7). However, by site-directed mutagenesis
A1
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B1
B2
C1
C2
D1
D2
E1
E2
F1
F2
Figure 3 Immunohistochemical analysis of PDCD4 shows the corresponding H&E-stained and PDCD4-stained tissue sections from
patients with OSCC. Panels A1, A2, D1, D2 show two adjacent normal epithelium samples with strongly positive, nuclear PDCD4 staining.
Panels B1, B2, E1, E2 show two dysplasia samples with positive to weak nuclear PDCD4 staining. Panels C1, C2, F1, F2 show loss of PDCD4
expression in two moderately differentiated OSCCs. Normal, dysplasia and OSCC samples are paired and correspond to two different patients
(A-C and D-F, respectively).
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Page 4 of 13(described below), we did show that miR-21 binds to the
3′UTR of PDCD4, causing its down-regulation.
PDCD4 regulation by miR-21 in OSCC
We showed that transient transfection of both PDCD4
and PDCD4-UTRmut led to up-regulation of PDCD4
compared to control. Co-transfection of miR-21 and
PDCD4 resulted in a significant decrease in PDCD4
protein expression; however when miR-21 was co-
transfected with PDCD4-UTRmut, PDCD4 protein
levels remained unchanged (Figure 8). These results
indicate that miR-21 directly binds to the PDCD4 3′
UTR in oral carcinoma cells.
Discussion
Herein, we identified PDCD4 under-expression at both
the mRNA and protein levels in primary patient OSCCs
and oral cancer cell lines. We showed that lower
PDCD4 expression levels were significantly associated
with regional disease (neck nodal metastasis), more
advanced tumor stages, and poorer survival and disease-
free survival of OSCC patients, suggesting that PDCD4
may have prognostic value in OSCC.
PDCD4 has been identified as a suppressor of tumori-
genesis with lost or reduced expression in cancers of
epithelial origin, including the lung [8], breast [11],
colon [12,13], esophagus [16], and ovary [25]. In both
lung [8] and ovarian [25] tumors, decreased or lost
PDCD4 expression was associated with disease progres-
sion. In addition, a consistent decrease in PDCD4
expression levels was associated with the steps from
normal to borderline to malignant ovarian tissues, and
PDCD4 over-expression in ovarian cancer cells resulted
in malignant growth inhibition [25]. In colon cancer,
PDCD4 levels were continuously lower in the normal-
adenoma-carcinoma sequence [12]. In other cancers,
PDCD4 was shown to have diagnostic [12], and prog-
nostic significance [8,26]. For example, loss of PDCD4
expression was correlated with poor patient prognosis,
higher tumor grade and stage in lung cancers [8],
shorter disease-free survival of ovarian cancer patients
[25], as well as with clinicopathological features of
tumor aggressiveness (e.g., nodal metastasis, advanced
tumor stage) in gastric cancer [26]. PDCD4 was also
shown to be an independent risk factor in colon [12,27]
and lung cancer [8].
Despite all of these studies showing PDCD4 deregula-
tion associated with important clinical parameters in
different cancers, the regulatory mechanisms of PDCD4
are still not completely understood. Recent research
indicates that PDCD4 play roles in transcription, trans-
lation of proteins important in neoplastic transforma-
tion, such as eukaryotic initiation factors (eIFs) [28], as
well cell signaling pathways; reviewed in [7]. PDCD4
regulates translation by interacting with the translation
initiation factors eIF4A and eIF4G1 [29-31]. PDCD4
directly interacts with eIF4A via its MA3-c domain
[28,32], inhibiting eIF4A helicase activity, and interrupt-
ing the assembly of the eIF4F complex [29,31,33], which
results in disrupted cap-dependent translation and inhi-
bition of cell transformation. Direct and indirect inter-
acting partners of PDCD4 and its targets is shown in
Figure 4 PDCD4 mRNA and PDCD4 protein levels in OSCC cell
lines. (A) The log10 ratio of PDCD4 mRNA in OSCC cell lines relative
to HOK. (B) Quantification of PDCD4 protein expression in OSCC cell
lines with a representative Western blot of PDCD4 protein in OSCC
cell lines below. Cell line data are plotted mean ± SE and are
representative of 3 separate experiments.
PCMV6 PDCD4
siRNA-
PDCD4
siRNA
ctrl
PDCD4
β-Actin
PDCD4
β-Actin
PDCD4
β-Actin
24A
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(52 kDA)
(42 kDA)
74A
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Figure 5 Western blotting analysis demonstrating over-
expression or knock-down of PDCD4 using PDCD4 plasmid or
PDCD4 targeted siRNA, respectively, versus control plasmids
(PCMV6, siRNA ctrl) in the UT-SCC cell lines (A) 24A, (B) 74A,
and (C) 87.
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Page 5 of 13Figure 9, which was generated using I2D database [34]
and NAViGaTOR network visualization system [35].
In our study, we showed that PDCD4 acted as a
negative regulator of invasion in OSCC cell lines. Simi-
lar to our findings, PDCD4 suppressed the invasion
and intravasation of colon cancer cells, implicating
PDCD4 as regulator of invasion and metastasis [27].
Furthermore, PDCD4 down-regulation was shown to
enhance invasion of colon cancer cells, by down-regu-
lation, at least in part, of the transcription factor AP-1
components (c-Jun and c-Fos) [13]. PDCD4 was shown
to act upstream of AP-1 to inhibit its activation. In
addition, PDCD4 was shown to interact with c-Jun and
to block its phosphorylation by JNK and prevent its
recruitment of p300, a histone acetyl transferase
required for transcription of AP-1 target genes by
c-Jun [36]. These mechanisms lead to inhibition of c-
Jun activity and down-regulation of AP-1 responsive
promoters and a less invasive phenotype in colon
cancer cell lines [18].
Other mechanistic studies in colon cancer showed that
PDCD4 knock-down activates b-catenin/Tcf-dependent
transcription and acts as a promoter of tumor cell inva-
sion [13]. A recent study in PDCD4 knock-down colon
cancer cell lines demonstrated that E-Cadherin loss is a
key event for activating the b-catenin/Tcf-dependent
transcription, leading to subsequent over-expression of
the invasion-promoter genes u-PAR and c-MYC [37].
Although these studies demonstrated mechanisms of
invasion regulated by PDCD4, the mechanisms that regu-
late PDCD4 in cancer cells are not well understood.
Mechanisms that are frequently involved in the down-
regulation of tumor suppressor genes commonly involve
mutational inactivation and deletion [38], however such
mechanisms seem not to apply to PDCD4. Several
mechanisms of PDCD4 down-regulation were reported,
such as hypermethylation of its 5′ promoter region in
glioma [39], increased proteasomal degradation [40], and
silencing by miR-21 [21].
miR-21 has been shown to down-regulate PDCD4,
leading to an increase in cell proliferation, invasion,
metastasis, and neoplastic transformation of breast
cancer lesions [15,41]. Additionally, miR-21 decreased
PDCD4 levels and increased invasion and metastasis in
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Figure 6 Representation of invasion (5× magnification, left panel) following over-expression or knock-down of PDCD4 using PDCD4
plasmid or PDCD4 targeted si-RNA, respectively, versus control (PCMV6 and siRNA ctrl) in the UT-SCC cell lines 24A, 74A, and 87. Cells
were stained with the Diff-quick stain set. The percentage of invading cells (right panel) is shown for each cell line. Post-transfection, we
observed a significantly decrease in the average percentage of invading cells, from 75% to 10% in UT-SCC-24A, from 113% to 17% in UT-SCC-
74A, and from 69% to 16% in UT-SCC-87. Knock-down of PDCD4 resulted in an increase in the number of invading cells, from 52% to 118% in
UT-SCC-24A, from 67% to 193% in UT-SCC-74A, and from 76% to 113% in UT-SCC-87.
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Page 6 of 13colorectal cancer [27]. In esophageal carcinoma, down-
regulation of miR-21 led to an increase in PDCD4 pro-
tein levels and a decrease in cellular proliferation and
invasion [16]. We previously showed that miR-21 has
continuously increasing over-expression during
progression of oral carcinoma [23]. Previous studies
have shown that PDCD4 is a putative target of miR-21
[21,41,42]. In our study, miR-21 over-expression in
PDCD4-negative OSCCs suggested a potential mechan-
ism of PDCD4 regulation by miR-21. We further
demonstrated that miR-21 binds to the 3′UTR of
PDCD4, causing its down-regulation. Our data thus sug-
gest a mechanism of PDCD4 regulation by miR-21, lead-
ing to PDCD4 under-expression in oral carcinoma.
Considering that PDCD4 functions as a tumor sup-
pressor gene and that it may have potential applications
as a therapeutic target [43], understanding PDCD4
expression patterns, regulation, and role in OSCC may
be valuable for exploring PDCD4 as a potential thera-
peutic target in OSCC.
Conclusions
Our study showed significant PDCD4 under-expression/
loss in malignant oral cavity tissues. Prominent loss of
PDCD4 expression in metastatic OSCCs, correlated with
poorer survival and poorer disease-free survival of
OSCC patients suggests that PDCD4 may be a clinically
relevant biomarker with prognostic value. PDCD4 loss
may be one of the crucial steps required for invasion
and metastasis of OSCC. In addition, our data also sug-
gest that PDCD4 under-expression in OSCC may be
regulated by miR-21.
Materials and methods
Patient Samples
This work was performed with the approval of the Uni-
versity Health Network Research Ethics Board. All
patients signed informed consent before sample collec-
tion and were untreated before surgery. Tissue samples
were obtained at time of surgery from the Toronto Gen-
eral Hospital, Canada. Patients are representative of the
typical OSCC population within North America [44].
This study included a total of 50 patients used for gene
expression analysis by quantitative RT-PCR (QPCR), and
immunohistochemical analysis (IHC), as described below.
QPCR: QPCR analysis was performed in 50 primary
patient OSCC samples. A subset of these patients (25/50)
also had adjacent normal tissue (> 0.5 cm away from the
tumor) collected. The detailed patient clinical data are
described in Table 1. A head and neck pathologist
(BP-O) performed histological evaluation of all samples
to ensure that tumor specimens contained at least 80% of
cancer cells and that all adjacent normal tissues did not
have any evidence of dysplasia. Primary OSCCs and his-
tologically normal samples were snap-frozen in liquid
nitrogen until RNA extraction. Of these 50 patients, 28
patients had blocks available and were used for IHC ana-
lysis. Clinical data for this subset of 28 patients show
Figure 7 Panel A shows miR-21 expression in pre-miR-21 or
anti-miR-21 transfected cells compared to control (miR-
scramble) in the UT-SCC cell lines 24A, 74A, and 87. Panel B
shows PDCD4 protein levels (Western blot) after transfection with
pre-miR-21 or anti-miR-21 compared to miR-scramble control. PCR
data plotted are the mean ± SE and are representative of 3
separate experiments. In the Western blot, PDCD4/b-Actin
represents the ratio of the band intensity of PDCD4 compared to
that of b-Actin, and are shown below the blots, for each cell line.
Panels A-C in the same line corresponds to the same cell line, in
this order (UT-SCC-24A, 74A and 87).
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Figure 8 The upper panel shows miR-21 expression levels
following transfection with pre-miR21, PDCD4 and PDCD4-
UTRmut, compared to controls: scramble miR and PCMV6
empty vector. miR-21 expression data are presented as Log10 fold
change, compared to mock-transfected control. Data are plotted as
mean ± SE and are representative of two separate experiments. The
lower panel shows the Western blot analysis of PDCD4 protein
levels for the different transfection conditions. PDCD4/b-Actin
represents the ratio of the band intensity of PDCD4 compared to
that of b-Actin, and is shown below each blot. Co-transfection of
miR-21 with PDCD4, but not PDCD4-UTRmut, resulted in a decrease
in PDCD4 protein expression.
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Page 7 of 13clinicopathological characteristics representative of the
original OSCC patient cohort [see Additional file 3].
Cell Lines
S i xO S C Cc e l ll i n e s( U T - S C C - 1 5 ,2 0 A ,2 4 A ,2 8 ,7 4 A ,
and 87), derived from primary patient samples, were
supplied by Dr. Reidar Grénman, University of Turku,
Finland [45]. Cell lines were maintained in Dulbecco’s
Modified Eagle Media (DMEM) containing 10% FBS, 1%
Penicillin-Streptomycin and 1% L-Glutamine, at 37°C in
a5 %C O 2 humidified incubator. A normal oral mucosa
cell line (Human Oral Keratinocyte, HOK, Invitrogen)
was used as control. HOK cells were maintained in oral
keratinocyte media, supplemented with 1% keratinocyte
growth factor plus epithelial growth factor mixture
(Invitrogen).
RNA Isolation
Total RNA was extracted from patient samples (OSCC
and normal tissues) and cell lines, using Trizol reagent
(Life Technologies, Inc., Burlington, ON, Canada),
followed by purification using the Qiagen RNeasy kit
and treatment with the DNase RNase-free set (Qiagen,
Valencia, CA, USA), all according to manufacturers’
instructions. RNA was quantified using Nanodrop 1000
(Nanodrop); quality was assessed using the 2100 Bioana-
lyzer (Agilent Technologies, Canada). The RNA samples
used were all of sufficient quality for gene expression
analysis.
QPCR Analysis
PDCD4 mRNA levels were examined in 50 OSCCs and
25 adjacent normal oral tissues, to verify whether PDCD4
was under-expressed in OSCCs and correlated with rele-
vant clinicopathological data of patients. QPCR analysis
was performed using the 7900 Sequence Detection Sys-
tem and the SYBR Green I fluorescent dye (Applied Bio-
systems, Foster City, CA) as previously described [5].
GAPDH was used as the internal control gene. Primer
sequences were: PDCD4 Forward: 5′-ggcctccaaggagtaa-
gacc-3′;R e v e r s e :5 ′-aggggtctacatggcaactg-3′ and GAPDH
Forward: 5′-aagggaaggttgctggatagg-3′;R e v e r s e :5 ′-
Figure 9 Protein-protein interaction network of PDCD4 targets. I2D version 1.72 was used to identify direct protein interactions for the
PDCD4 targets (highlighted as diamond-shape nodes; n = 8). The resulting network of 523 proteins and 3,941 interactions was visualized using
NAViGaTOR 2.1.14 http://ophid.utoronto.ca/navigator. Color of nodes corresponds to Gene Ontology biological function; shape of nodes
represents different types of important proteins; color of edges represents different interactions among targets, as described in the legend. Blue
edges signify direct interactions among PDCD4 targets. Green-highlighted nodes represent proteins interacting with at least two PDCD4 targets,
and green edges identify corresponding interactions with PDCD4 targets. Red-highlighted nodes represent central proteins, and thick edges
represent central interactions, and orange edges show direct interactions among central proteins and PDCD4 targets. Remaining nodes and
edges were faded out to reduce network complexity. Network representation in XML file for NAViGaTOR, and annotation table, are provided in
supplementary material.
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Page 8 of 13cacatccacctcctccacatc-3′. Reactions were performed in
triplicate for each sample and primer set. Dissociation
curves were run for all reactions to ensure primer specifi-
city and lack of PCR artifact. PCR products of randomly
selected reactions were run on 1.5% agarose gels and
visualized under UV, to verify presence of the appropri-
ate-sized amplicon. PDCD4 mRNA levels in OSCC were
normalized against 25 adjacent normal oral samples.
Data were analyzed using the Delta Delta Ct method
[5,46].
Immunohistochemistry (IHC)
Tumor samples from 28/50 OSCC patients were ana-
lyzed by IHC. H&E-stained sections were examined for
each patient. OSCCs included adjacent normal tissue
in the same tissue section, which was used as the nor-
mal control. Tissue sections (4 μm) were cut from
FFPE blocks and IHC staining was performed using
the Avidin-Biotin method [47]. Sections were incu-
bated with epitope-specific primary antibody against
rabbit anti-human PDCD4 (600-401-964, Rockland
Immunochemicals, Gilbertsville, PA, USA). For nega-
tive controls, antibody was omitted and antibody dilu-
ent alone or isotype matched IgG serum was used.
Normal oral mucosa was useda sap o s i t i v ec o n t r o l .
IHC Scoring Analysis
PDCD4 expression was evaluated semi-quantitatively
[48], considering staining intensity (0 = absent; 1 =
low; 2 = similar to normal epithelium; 3 = higher than
normal) and percentage of positively stained cells (1 =
immunostaining in ≤ 10% of cells; 2 = 11-30%; 3 =
31-60%; 4 = 61-100%). The final score was calculated
by adding the intensity and percentage scores. Scores
1-4 represented absent/weak or under-expression and
scores 5-7 represented no change or higher expression
compared to adjacent normal. Slides were scored inde-
pendently in a blinded fashion by three observers
(B.P-O, PPR, and MT); the head and neck pathologist
(B.P-O) examined all slides to ensure immunostaining
specificity and quality.
Statistical Analyses
Associations between PDCD4 mRNA expression and
clinicopathological data were performed using the Rank-
Sum test. The Fisher’s exact test was used to correlate
PDCD4 protein expression and clinical data. PDCD4
protein expression was dichotomized as negative
(under-expressed) for scores 1-4 and positive (no-change
or over-expressed) for scores 5-7.
Table 1 Clinical and histological characteristics of
samples (QRT-PCR analysis - 50 patients)
Variables N (%)
Age (years)
Median (range) 67 (43-87)
Gender
Male 36 (72)
Female 14 (28)
Tobacco use
Yes 38 (76)
No 12 (24)
Alcohol use
Yes 34 (68)
No 16 (32)
Tumor Site
Tongue 33 (66)
Floor of mouth 10 (20)
Alveolar 4 (8)
Buccal mucosa 2 (4)
Retromolar 1 (2)
T category
T1-T2 16 (32)
T3-T4 34 (68)
Nodal status (pathological)
Negative (N0) 28 (56)
Positive (N1, N2b, N2c) 22 (44)
Tumor Stage
I-II 14 (28)
III-IV 36 (72)
Tumor Grade
Well differentiated 4 (8)
Moderately differentiated 41 (82)
Poorly differentiated 5 (10)
Tumor thickness (mm)
Median (range) 12 (2-31)
Perineural invasion
Yes 20 (40)
No 30 (60)
Angiolymphatic invasion
Yes 16 (32)
No 34 (68)
Recurrence
Yes 23 (46)
No 27 (54)
Outcome*
Alive, no evidence of disease 25 (50)
Alive with disease 6 (12)
Dead of disease 15 (30)
Dead of other causes 4 (8)
* last date of follow-up: October, 2009.
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as T1-T2 vs.T 3-T4,a n df o rNc a t e g o r y ,t u m o r sw e r e
grouped as node negative (N0) vs. node positive (N1,N 2
and N3). Overall survival analysis was done using the
Kaplan-Meier method. Survival was defined as the time
between surgery date and death or last follow-up.
Disease free survival (DFS) was defined as time between
surgery date and recurrence or death or last follow-up.
Statistical significance of differences between survival
curves was assessed using Log-Rank test; Hazard Ratios
(HR) and Confidence Intervals (CI) were calculated.
Protein-protein interaction network
In order to determine functional relationships among
the PDCD4 targets we mapped the 8 proteins (PDCD4,
eIF4A, eIF4G1, JUN, c-FOS, CTNNB1, TCF (HNF4A),
CDH1) to their corresponding SwissProt identifiers
(SPIDs) [see Additional file 4]. All SPIDs were subse-
q u e n t l yu s e dt od e f i n eap r o t e in-protein interaction
(PPI) network by querying Interologous Interaction
Database (I2D; v1.72; http://ophid.utoronto.ca/i2d, with
an update for BioGrid, DIP, HPRD, IntAct, MINT PPI
data obtained 1/2010) [34]. PPI data for multiple SPIDs
that map to the same gene (i.e., same Entrez Gene ID)
were combined. The identified interacting proteins were
then used to query the same database to determine
whether any interactions are present between them to
form the complete five prognostic signatures PPI net-
work. PPI networks were visualized, annotated and ana-
lyzed using NAViGaTOR v2.1.14 http://ophid.utoronto.
ca/navigator/ [35].
Plasmids
We used a commercially available PDCD4 expression
plasmid, PCMV6-XL4-PDCD4 (Origene) and a control
plasmid, PCMV6-XL4 (PCMV6; Origene). The PDCD4
plasmid consisted of the 2,640 base pair PDCD4 cDNA
sequence (RefSeq: NM_014456) inserted into the
PCMV6 multi-cloning site. E. coli cells were trans-
formed with each plasmid and selectively expanded in
ampicillin, using standard protocols. DNA was extracted
using the Plasmid Midi-prep Kit (Qiagen) according to
the manufacturer’s protocol. DNA was quantified using
Nanodrop 1000 (Nanodrop). In order to knock-down
PDCD4 expression, we used a PDCD4 siRNA (50 μM)
and control siRNA (50 μM) (Santa Cruz Biotechnology,
CA, USA).
Transfection
Cell lines were seeded in 6-well plates (2×10
5 cells/well)
in DMEM containing 10% FBS, 1% Penicillin-Streptomy-
cin and 1% L-Glutamine. Subsequently, cells were tran-
siently transfected using previously described protocols
[48], with either empty vector, PCMV6-XL4 (PCMV6;
Origene), PCMV6-XL4-PDCD4 (PDCD4; Origene), 50
pmol of control si-RNA or PDCD4 si-RNA (Santa
Cruz), 50 pmol of scramble-miR, pre-miR-21 or anti-
miR-21 (Ambion) using Lipofectamine-2000 reagent
(Invitrogen). Successful transfection without affecting
cell viability was obtained for 3 cell lines (UT-SCC-24A,
74A, and 87). Transfection was confirmed by QPCR and
Western blotting.
Transwell Invasion Assay
We next carried out a transwell invasion assay to evalu-
ate the invasive potential of 3 cell lines (UT-SCC-24A,
74A, and 87), which were successfully transfected with
PDCD4, PDCD4 si-RNA or controls (mock, PCMV6
vector or si-scramble transfected). Transwell invasion
assay experiments were carried out as previously
described [48]. Cells that invaded the lower surface of
the Matrigel-coated membrane were stained using the
Diff Quick Stain set (Dade Behring, Newark, Del) and
fixed onto a glass slide. The number of invading cells
was quantified using NIH-ImageJ software [49] and nor-
malized to mock-transfected controls. Data are repre-
sentative of 3 independent experiments (biological
replicates).
Western Blotting
Samples were harvested from UT-SCC cell lines, total pro-
tein was extracted and protein concentration was deter-
mined using the Bradford Assay (Bio-Rad) as per
manufacturer’s instructions. Western blotting was per-
formed using 25 μg of protein, according to standard pro-
cedures [48]. Immunodetection was done using anti-rabbit
monoclonal antibody against PDCD4 (Rockland), diluted
1:5,000, followed by incubation with anti-rabbit secondary
antibody (horseradish peroxidase HRP-conjugated) (GE
Healthcare), diluted 1:5,000, for chemiluminescent detec-
tion. Anti-mouse monoclonal b-Actin (HRP-conjugated)
(Santa Cruz), diluted 1:50,000 was used as control. The
ECL plus detection system (GE Healthcare) was used, and
signal intensities were determined by Image J software
[49]. PDCD4 protein expression was determined semi-
quantitatively based on ratio of the signal intensity of
PDCD4 to b-Actin.
PDCD4 transfection did not affect cell viability, as ver-
ified by flow cytometry analysis using propidium iodide
staining (Becton Dickinson FACS caliber, CellQuest
software) (data not shown).
In Silico Analysis for miR-21 Binding Sites
Since miR-21 is predicted to target PDCD4 [19,50,51],
we sought to determine whether PDCD4 was a direct
target of miR-21 in UT-SCC cell lines, or whether miR-
21 was indirectly regulating PDCD4 by targeting another
gene. For this, we first identified the sequence of
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using the online resource microRNA.org [20,52].
According to this analysis, miR-21 was predicted to
bind PDCD4 with an alignment score of 157, based on
the number of matching base pairs between the miR
and its predicted binding site. Previous reports con-
firmed this potential miR-21 binding site at the 3′UTR
of PDCD4 [41,53].
Detection of miR-21 levels by TaqMan PCR
miR-21 levels were examined in the 28 patient OSCCs
that had both PDCD4 mRNA and protein data available.
PCR-based detection of mature miR-21 was performed
using the TaqMan micro-RNA assays (Applied Biosys-
tems). RT reactions were carried out using 100 ng total
RNA by Multi-Scribe Reverse Transcriptase (50 units)
in the presence of 1 mM dNTPs, 1× Reverse Transcrip-
tion Buffer (Ambion) and RNase inhibitor (0.25 units)
and miR-specific primers against the target sequences
(miR-21, 5′-uagcuuaucagacugauguuga-3′;R N U 4 4e n d o -
genous control, 5′-ccuggaugaugauagcaaaaugcugacugaa-
caugaaggucuuaauuagcucuaacugacu-3′). miR-21 levels
were normalized against RNU44 endogenous control
miR [23], and calculated using the Delta Delta Ct
method [5,46].
Site-directed mutagenesis assay
The full length PDCD4 sequence (Origene) was used as
a template to introduce mutations at the miR-21 bind-
ing site (PDCD4-UTRmut). This assay used the Quik-
Change Lightning Site-Directed Mutagenesis Kit
(Stratagene). Briefly, PCR (18 cycles; annealing tempera-
ture of 68°C) was performed using PDCD4 as template
and primers designed to introduce point mutations
(bold); Forward: 5′-ggagggacagaaaagtaacctcttaagtggaa-
tattctaaggaattcccttttgtaagtgcc-3′; Reverse: 5′-ggcactta-
caaaaggcccgggcttagaatattccacttaagaagaggttacttttctgtg
tccctcc-3′. The PCR product was digested with the DpnI
restriction enzyme, to remove any non-mutated DNA
template. The digestion product was then transformed
into competent DH5-alpha cells and plated onto ampi-
cillin (50 ng/mL) coated agar plates; colonies were
expanded and plasmid DNA was extracted using the
Plasmid Mini-prep Kit (Qiagen). Sequencing analysis
was performed and confirmed the presence of the
PDCD4-UTRmut. PDCD4-UTRmut plasmid was then
expanded in E. coli and plasmid DNA was extracted
using the Plasmid Midi-prep Kit (Qiagen). 200 ng of
PDCD4 or PDCD4-UTRmut plasmid were co-trans-
fected with 50 pmol pre-miR-21 or scramble-miR (con-
trol) (Ambion). The pre-miR-21, anti-miR-21 and
control miR (Ambion) were re-suspended in nuclease-
free water to a concentration of 50 μM. Transfection
experiments were performed in UT-SCC74A, as
previously described [48]. RNA and protein were
isolated after 72 hrs. Transfection of PDCD4 and pre-
miR-21 was confirmed by Western blotting and QPCR,
respectively.
Additional material
Additional file 1: Cell viability of UT-SCC-24A after transfection with
200 ng, 500 ng, 1000 ng or 2000 ng of either PDCD4 or PCMV6
control plasmid compared to mock-transfected.
Additional file 2: (A) Representation of invasion of UT-SCC-24A
transfected with either transfection reagent alone (Lipofectamine-
2000; mock), 200 ng or 500 ng PCMV6 or PDCD4 plasmid; (B)
Quantification of invasion. Data are plotted mean ± SE.
Additional file 3: Clinical details of the 28 patients used for PDCD4
IHC analysis. These are a subset of patients shown in Table 1.
Additional file 4: PDCD4 network representation in XML file for
NAViGaTOR, and annotation table.
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